Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement
(firmenpresse) - SAN DIEGO, CA -- (Marketwire) -- 09/23/11 -- Cytori Therapeutics (NASDAQ: CYTX) has entered into a Celution® System agreement with Apollo Hospitals, one of Asia's largest private healthcare groups, to offer the technology initially at select cosmetic surgery centers in India.
"At Apollo Hospitals, we pride ourselves on introducing the latest technological medical advancements," said Dr. Prathap C. Reddy, founder and Chairman of Apollo Hospitals Group. "The alliance with Cytori has the potential to revolutionize the delivery of personalized cell therapy in India. The Cytori Celution® System represents best-in-class regenerative medicine technology that enables surgeons' access to the power of the patient's own regenerative cells as real-time therapy for cosmetic surgery as well as a variety of other ischemic conditions."
Apollo Hospitals is a core customer around which Cytori can build a successful commercial business in India. This agreement follows a clinical evaluation of Celution®-based soft tissue procedures performed by Apollo. More information about Apollo Hospitals Group can be found at .
Cytori is a leader in cell therapy, providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft™ products are available in North America and Europe for fat grafting procedures.
This communication includes forward-looking statements regarding events, trends and business prospects, such as building a successful commercial business in India, which may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.
Tom Baker
+1.858.875.5258
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.09.2011 - 12:00 Uhr
Sprache: Deutsch
News-ID 68932
Anzahl Zeichen: 0
contact information:
Town:
SAN DIEGO, CA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 279 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytori & Apollo Hospitals Group of India Formalize Celution(R) Agreement"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytori Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
